Rudolf Li
Position：
Head of Quality
Education Background：
Ph.D. in Cell Biology, University of Science & Technology of China
Profile：
Dr. Rui Li is a seasoned immuno-oncology expert with 17+ years of experience spanning basic research and the end-to-end development of cell therapies. Before joining Neukio, he served as Head of Quality Control at Fosun Kite (now Fosun Kairos), where he was instrumental in the successful launch of China's first approved CAR T-cell therapy, axicabtagene ciloleucel (Yescarta®/Yikaida®). His leadership covered the full journey, from the initial technology transfer from Kite Pharma to the successful IND/BLA filings, NMPA approval, and commercialization. Dr. Li’s expertise encompasses product quality management, QC operations management, and regulatory affairs. At Neukio, he focuses on developing next-generation, off-the-shelf (allogeneic) immune cell therapies, aiming to deliver novel and accessible treatments to patients.